Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Assets Growth (1y)Assets Growth (3y)Assets Growth (5y)Capital Expenditures Growth (1y)Capital Expenditures Growth (3y)Capital Expenditures Growth (5y)Cash & Equivalents Growth (1y)Cash & Equivalents Growth (3y)Cash & Equivalents Growth (5y)Cash from Investing Activities Growth (1y)Cash from Investing Activities Growth (3y)Cash from Investing Activities Growth (5y)Cash from Operations Growth (1y)Cash from Operations Growth (3y)Cash from Operations Growth (5y)EBIT Growth (1y)EBIT Growth (3y)EBIT Growth (5y)EBIT Margin Growth (1y)EBIT Margin Growth (3y)EBIT Margin Growth (5y)EBITDA Margin Growth (1y)EBITDA Margin Growth (3y)EBITDA Margin Growth (5y)EBT Growth (1y)EBT Growth (3y)EBT Growth (5y)EBT Margin Growth (1y)EBT Margin Growth (3y)EBT Margin Growth (5y)EPS (Basic) Growth (1y)EPS (Basic) Growth (3y)EPS (Basic) Growth (5y)Enterprise Value Growth (1y)Enterprise Value Growth (3y)Enterprise Value Growth (5y)FCF Margin Growth (1y)FCF Margin Growth (3y)FCF Margin Growth (5y)Free Cash Flow Growth (1y)Free Cash Flow Growth (3y)Free Cash Flow Growth (5y)Gross Margin Growth (1y)Gross Margin Growth (3y)Gross Margin Growth (5y)Gross Profit Growth (1y)Gross Profit Growth (3y)Gross Profit Growth (5y)Interest Coverage Ratio Growth (1y)Interest Coverage Ratio Growth (3y)Interest Coverage Ratio Growth (5y)Net Cash Flow Growth (1y)Net Cash Flow Growth (3y)Net Cash Flow Growth (5y)Net Income Growth (1y)Net Income Growth (3y)Net Income Growth (5y)Net Income towards Common Stockholders Growth (1y)Net Income towards Common Stockholders Growth (3y)Net Income towards Common Stockholders Growth (5y)Net Margin Growth (1y)Net Margin Growth (3y)Net Margin Growth (5y)Operating Income Growth (1y)Operating Income Growth (3y)Operating Income Growth (5y)Operating Margin Growth (1y)Operating Margin Growth (3y)Operating Margin Growth (5y)Profit After Tax Growth (1y)Profit After Tax Growth (3y)Profit After Tax Growth (5y)Property, Plant & Equipment (Net) Growth (1y)Property, Plant & Equipment (Net) Growth (3y)Property, Plant & Equipment (Net) Growth (5y)Return on Assets Growth (1y)Return on Assets Growth (3y)Return on Assets Growth (5y)Return on Capital Employed Growth (1y)Return on Capital Employed Growth (3y)Return on Capital Employed Growth (5y)Return on Equity Growth (1y)Return on Equity Growth (3y)Return on Equity Growth (5y)Return on Sales Growth (1y)Return on Sales Growth (3y)Revenue Growth (1y)Revenue Growth (3y)Revenue Growth (5y)Shareholder's Equity Growth (1y)Shareholder's Equity Growth (3y)Shareholder's Equity Growth (5y)
Income Statement
Others
Ratios

Immuron (IMRN) Net Income towards Common Stockholders Growth (1y) (2017 - 2024)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (1y) (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -58.11%
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -95.76%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -290.15%
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 59.59%
7 Evaxion A 62.56 Bn 62.54 Bn - -129.68%
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -10.08%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 1,228.66%
10 Immuron 1.27 Bn 1.27 Bn - -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2024 21.49%
Dec 31, 2023 -213.46%
Dec 31, 2022 13,946.40%
Dec 31, 2021 77.00%
Dec 31, 2020 -277.25%
Dec 31, 2019 99.04%
Dec 31, 2018 -141.21%
Dec 31, 2017 50.20%